Table 3.
Treatment-emergent adverse events
| Zanubrutinib (n = 28) | ||
|---|---|---|
| All grades | Grade ≥3 | |
| Event term, n (%)* | ||
| Diarrhea | 8 (29) | 2 (7) |
| Upper respiratory tract infection | 6 (21) | 0 |
| Contusion | 6 (21) | 0 |
| Pyrexia | 6 (21) | 0 |
| Cough | 5 (18) | 0 |
| Respiratory tract infection | 5 (18) | 2 (7) |
| Pruritis | 4 (14) | 0 |
| Decreased appetite | 4 (14) | 0 |
| Muscle spasms | 4 (14) | 0 |
| Peripheral edema | 4 (14) | 0 |
| Fatigue | 4 (14) | 0 |
| Pneumonia | 4 (14) | 2 (7) |
| Urinary tract infection | 4 (14) | 0 |
| Constipation | 4 (14) | 0 |
| Back pain | 4 (14) | 0 |
| Rash | 3 (11) | 1 (4) |
| Arthralgia | 3 (11) | 0 |
| Headache | 3 (11) | 0 |
| Basal cell carcinoma | 3 (11) | 0 |
| Herpes zoster | 3 (11) | 0 |
| Skin laceration | 3 (11) | 0 |
| Hyponatremia | 2 (7) | 2 (7) |
| Adverse events of interest, n (%) | ||
| All Infections | 21 (75) | 8 (29) |
| All hemorrhages | 11 (39) | 2 (7) |
| Major hemorrhages | 2 (7) | 2 (7) |
| Hypertension | 3 (11) | 3 (11) |
| Anemia | 6 (21) | 3 (11) |
| Neutropenia | 5 (18)† | 3 (11)† |
| Thrombocytopenia | 3 (11) | 2 (7) |
| Second primary malignancies | 4 (14) | 0 |
| Skin cancers | 4 (14) | 0 |
*
Data are for all grade treatment-emergent adverse events reported in ≥10% of patients or ≥5% of patients for events grade ≥3. Events are listed in descending order of frequency by all-grade incidence.
†
Includes the MedDRA preferred term “neutrophil count decreased.”